The results build upon Acumen’s prior presentations at the AD/PD™ 2024 Annual Meeting and positive topline data first announced in July 2023, highlighting sabirnetug as the first humanized monoclonal antibody to clinically demonstrate selective target engagement of synaptotoxic AβOs. Additional information can be found here.

May 14, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that ...

Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (NASDAQ:BFRI)

Banzai International, Inc. ( NASDAQ: BNZI) (“Banzai” or the “Company”), a leading SaaS marketing technology company, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Summary and Recent Operational Highlights Annual Recurring Revenue (“ARR”) for March 2024 was $4.

Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex,

Bio-Path Holdings Reports First Quarter 2024 Financial Results Marks Progress Across Key Clinical and Corporate Goals Strengthened Balance Sheet with

Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA

Wong, Founder and CEO of HCW Biologics, stated, “We reached an important clinical development milestone in the first quarter of 2024. Enrollment was completed in two ongoing clinical trials to evaluate HCW9218 in solid tumors.